Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot feasibility study of two adjuvant chemotherapy regimens incorporating dose-dense docetaxel in early breast cancer
2009-015658-39Phase 2Active
- Sponsor
- Azienda USL 4 Prato
- Start
- Sep 2009
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of docetaxel, epirubicin, cyclophosphamide, capecitabine and vinorelbine in breast cancer (2 arms), sponsored by Azienda USL 4 Prato. Primary endpoint: Treatment-related toxicity for each regimen. Started Sep 2009; status: active.
02
Drugs
docetaxelepirubicincyclophosphamidecapecitabinevinorelbine
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2009-015658-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015658-39.